End-of-life care is of particular concern for elderly patients with AML because prognosis is poor and has not changed in several decades. Median survival for patients 65 or older is roughly two months and drops to as low as one month for patients over 85 years.
Eunice Wang, M.D., discusses a promising new drug for the treatment of certain patients with acute myeloid leukemia.
Besponsa (inotuzumab ozogamicin) was granted FDA approval for certain patients with ALL.
Driven by personal experience and his love for art, Ryan Berardi created a 3D animation that would help health care professionals if they wrongly administer chemotherapy to patients.
Vyxeos (CPX-351) was granted FDA approval for two subtypes of acute myeloid leukemia.
Idhifa (enasidenib) was granted approval by the Food and Drug Administration (FDA) today, for the treatment of patients who have relapsed or refractory IDH2-mutated acute myeloid leukemia (AML).
A recent study found that children of older parents may have an increased risk of certain types of cancers.
Blincyto (blinatumomab) was granted full approval by the Food and Drug Administration (FDA) to treat both children and adults with relapsed/refractory B-cell precursor acute lymphoblastic leukemia (ALL), regardless of Philadelphia chromosome (Ph) status, according to the developer of the anti-CD19 immunotherapy, Amgen.
Children with Philadelphia chromosome-positive chronic phase chronic myeloid leukemia (CP Ph+ CML) may soon have a new treatment
My wife and I are always amazed at the fond memories and warm feelings that rise up when we return to Nashville.
ClearLLab multicolor reagents (T1, T2, B1, B2, M) gained approval from the Food and Drug Administration (FDA) to detect chronic leukemia, acute leukemia, non-Hodgkin lymphoma, multiple myeloma, myelodysplastic syndrome (MDS) and myeloproliferative neoplasms (MPN). This is the first approval the agency received for immunophenotyping on a flow cytometer.
Rituxan Hycela (rituximab) was granted approval by the Food and Drug Administration (FDA) for adult patients with previously untreated and relapsed or refractory follicular lymphoma, previously untreated diffuse large B-cell lymphoma (DLBCL) and previously untreated and previously treated chronic lymphocytic leukemia (CLL).
Imbruvica (ibrutinib) continues to demonstrate benefit in patients with chronic lymphocytic leukemia (CLL) who had at least one prior therapy, according to a four-year follow-up of the RESONATE study, which compared the BTK inhibitor to Arzerra (ofatumumab).
VYXEOS (CPX-351), a novel injection, was granted a new drug application (NDA) by the Food and Drug Administration (FDA), granting the drug a priority review for the treatment of acute myeloid leukemia (AML), according to Jazz Pharmaceuticals, the producer of the drug.
Experts discuss how to have the best chances for a complete response for patients with chronic lymphocytic leukemia (CLL) who developed Hodgkin lymphoma (HL).
The Food and Drug Administration has approved Rydapt (midostaurin) for acute myeloid leukemia (AML).
"Neither feels guilty about surviving — although both have had plenty of reminders that they’re dealing with cancer — and both have found ways to continue enjoying life."
All members of the FDA’s Oncologic Drugs Advisory Committee (ODAC) voted to approve Rituxan for the treatment of some blood cancers.
Jim Kochenderfer, M.D., lends insight to the future of CAR T-cell therapy for hematologic malignancies.
Just one person can make a difference for patients with blood cancer.
Hope is growing for patients who are living with CML.
In a recent study, Blincyto (blinatumomab) had longer survival rates than standard chemotherapy for certain patients with ALL.
As Ed completes his final chemo cycle, he loses a friend.
More people with AML who were treated with Vyxeos were moved to transplant than those treated with a standard chemotherapy regimen, according to recent findings.
Inotuzumab ozogamicin was granted a priority review designation for patients with relapsed or refractory ALL.
